Literature DB >> 11890654

"Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate.

M C Hochberg1, J K Tracy, R H Flores.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11890654      PMCID： PMC1766673          DOI： 10.1136/ard.60.90003.iii51

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  18 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

Review 2.  Long acting drug combinations in rheumatoid arthritis: a formal overview.

Authors:  M Boers; M Ramsden
Journal:  J Rheumatol       Date:  1991-03       Impact factor: 4.666

3.  Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years.

Authors:  J M Kremer
Journal:  Arthritis Rheum       Date:  1997-05

Review 4.  Rational use of new and existing disease-modifying agents in rheumatoid arthritis.

Authors:  J M Kremer
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

5.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

6.  World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.

Authors:  M Boers; P Tugwell; D T Felson; P L van Riel; J R Kirwan; J P Edmonds; J S Smolen; N Khaltaev; K D Muirden
Journal:  J Rheumatol Suppl       Date:  1994-09

Review 7.  Cytokines in autoimmunity.

Authors:  F M Brennan; M Feldmann
Journal:  Curr Opin Immunol       Date:  1992-12       Impact factor: 7.486

8.  Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.

Authors:  P Tugwell; T Pincus; D Yocum; M Stein; O Gluck; G Kraag; R McKendry; J Tesser; P Baker; G Wells
Journal:  N Engl J Med       Date:  1995-07-20       Impact factor: 91.245

9.  Efficacy of low-dose methotrexate in rheumatoid arthritis.

Authors:  M E Weinblatt; J S Coblyn; D A Fox; P A Fraser; D E Holdsworth; D N Glass; D E Trentham
Journal:  N Engl J Med       Date:  1985-03-28       Impact factor: 91.245

Review 10.  Combination therapy in rheumatoid arthritis: updated systematic review.

Authors:  A C Verhoeven; M Boers; P Tugwell
Journal:  Br J Rheumatol       Date:  1998-06
View more
  10 in total

Review 1.  Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.

Authors:  M C Hochberg; J K Tracy; M Hawkins-Holt; R H Flores
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 2.  Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Elizabeth Tanjong Ghogomu; Ahmed Kotb; Robin Christensen; Amy S Mudano; Lara J Maxwell; Nipam P Shah; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2016-05-13

Review 3.  Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.

Authors:  Christine R Culy; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients.

Authors:  Paul Ornetti; Hélène Chevillotte; Amal Zerrak; Jean Francis Maillefert
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Limits of add-on trials: antirheumatic drugs.

Authors:  Laura Ottolenghi; Vittorio Bertele'; Silvio Garattini
Journal:  Eur J Clin Pharmacol       Date:  2008-09-03       Impact factor: 2.953

6.  N-of-1 trials of expensive biological therapies: a third way?

Authors:  Richard L Kravitz; Naihua Duan; Richard H White
Journal:  Arch Intern Med       Date:  2008-05-26

7.  What ever happened to N-of-1 trials? Insiders' perspectives and a look to the future.

Authors:  Richard L Kravitz; Naihua Duan; Edmund J Niedzinski; M Cameron Hay; Saskia K Subramanian; Thomas S Weisner
Journal:  Milbank Q       Date:  2008-12       Impact factor: 4.911

Review 8.  Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.

Authors:  Wanruchada Katchamart; Judith Trudeau; Veerapong Phumethum; Claire Bombardier
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 9.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Authors:  Cecilia Beatrice Chighizola; Voon H Ong; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 10.817

Review 10.  Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  W Katchamart; J Trudeau; V Phumethum; C Bombardier
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.